Log In
BCIQ
Print this Print this
 

HuMax-CD4, zanolimumab

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman mAb against CD4
Molecular Target CD4
Mechanism of ActionBinds CD4; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8.0M

$7.0M

$5.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/06/2011

$8.0M

$2.5M

$5.5M

02/08/2010

Undisclosed

$4.5M

Undisclosed

Get a free BioCentury trial today